Lophora is a preclinical biotech company. The company has identified and patented a new class of proprietary compounds with a similar pharmacological profile to psilocybin, which has shown promising clinical results in treating a variety of conditions such as depression and addiction.
The company is currently bringing its first-in-class lead molecule LPH-5 through pre-clinical toxicological evaluation and expects to be ready for IND/CTA submission by the end of 2021, allowing for the initiation of clinical trials in early 2022.
Based on +10 years of research from the University of Copenhagen, Lophora was founded in 2018 with the ambition of developing a novel class of proprietary small molecules with a unique selectivity profile to address conditions with significant unmet need such as Treatment-Resistant Depression, whose patients remain largely underserved.